Unknown Manufacturer
Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
Meplazumab is an anti-CD147 antibody, which is a recepor on host cells for viruses such as SARS-CoV2. Meplazumab's inhibition of CD147 binding to the spike proteins of viruses is thought to inhibit their entry.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
